vs

Side-by-side financial comparison of Princeton Bancorp, Inc. (BPRN) and SUTRO BIOPHARMA, INC. (STRO). Click either name above to swap in a different company.

Princeton Bancorp, Inc. is the larger business by last-quarter revenue ($20.7M vs $11.6M, roughly 1.8× SUTRO BIOPHARMA, INC.). On growth, Princeton Bancorp, Inc. posted the faster year-over-year revenue change (3.6% vs -21.4%). Over the past eight quarters, Princeton Bancorp, Inc.'s revenue compounded faster (9.1% CAGR vs -5.4%).

Princeton Bancorp, Inc. is a U.S.-based bank holding company operating through its community banking subsidiary. It offers retail and commercial banking products including deposit accounts, small business loans, consumer loans, mortgages and wealth management services, primarily serving clients across New Jersey and the U.S. mid-Atlantic region.

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in Ja...

BPRN vs STRO — Head-to-Head

Bigger by revenue
BPRN
BPRN
1.8× larger
BPRN
$20.7M
$11.6M
STRO
Growing faster (revenue YoY)
BPRN
BPRN
+24.9% gap
BPRN
3.6%
-21.4%
STRO
Faster 2-yr revenue CAGR
BPRN
BPRN
Annualised
BPRN
9.1%
-5.4%
STRO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BPRN
BPRN
STRO
STRO
Revenue
$20.7M
$11.6M
Net Profit
$6.1M
Gross Margin
Operating Margin
38.2%
Net Margin
29.3%
Revenue YoY
3.6%
-21.4%
Net Profit YoY
16.3%
35.4%
EPS (diluted)
$0.89

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BPRN
BPRN
STRO
STRO
Q4 25
$20.7M
$11.6M
Q3 25
$21.5M
$9.7M
Q2 25
$21.1M
$63.7M
Q1 25
$20.9M
$17.4M
Q4 24
$20.0M
$14.8M
Q3 24
$19.2M
$8.5M
Q2 24
$18.1M
$25.7M
Q1 24
$17.4M
$13.0M
Net Profit
BPRN
BPRN
STRO
STRO
Q4 25
$6.1M
Q3 25
$6.5M
$-56.9M
Q2 25
$688.0K
$-11.5M
Q1 25
$5.4M
$-76.0M
Q4 24
$5.2M
$-72.4M
Q3 24
$-4.5M
$-48.8M
Q2 24
$5.1M
$-48.0M
Q1 24
$4.3M
$-58.2M
Operating Margin
BPRN
BPRN
STRO
STRO
Q4 25
38.2%
Q3 25
38.5%
-499.9%
Q2 25
2.8%
-5.2%
Q1 25
32.9%
-393.8%
Q4 24
34.0%
-440.7%
Q3 24
-29.1%
-797.2%
Q2 24
34.1%
-189.4%
Q1 24
31.0%
-435.0%
Net Margin
BPRN
BPRN
STRO
STRO
Q4 25
29.3%
Q3 25
30.0%
-586.6%
Q2 25
3.3%
-18.0%
Q1 25
25.7%
-436.6%
Q4 24
26.1%
-489.2%
Q3 24
-23.3%
-572.6%
Q2 24
28.4%
-186.8%
Q1 24
24.9%
-447.5%
EPS (diluted)
BPRN
BPRN
STRO
STRO
Q4 25
$0.89
Q3 25
$0.95
$-0.67
Q2 25
$0.10
$-0.14
Q1 25
$0.77
$-0.91
Q4 24
$0.75
$-27.63
Q3 24
$-0.68
$-0.59
Q2 24
$0.80
$-0.59
Q1 24
$0.68
$-0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BPRN
BPRN
STRO
STRO
Cash + ST InvestmentsLiquidity on hand
$141.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$270.7M
$-132.5M
Total Assets
$2.3B
$173.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BPRN
BPRN
STRO
STRO
Q4 25
$141.4M
Q3 25
$167.6M
Q2 25
$205.1M
Q1 25
$249.0M
Q4 24
$316.9M
Q3 24
$388.3M
Q2 24
$375.6M
Q1 24
$267.6M
Total Debt
BPRN
BPRN
STRO
STRO
Q4 25
Q3 25
$0
Q2 25
$10.0M
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BPRN
BPRN
STRO
STRO
Q4 25
$270.7M
$-132.5M
Q3 25
$266.6M
$-87.3M
Q2 25
$261.9M
$-32.1M
Q1 25
$267.0M
$-25.8M
Q4 24
$262.0M
$44.6M
Q3 24
$261.5M
$111.2M
Q2 24
$244.8M
$152.2M
Q1 24
$241.8M
$98.0M
Total Assets
BPRN
BPRN
STRO
STRO
Q4 25
$2.3B
$173.8M
Q3 25
$2.2B
$209.7M
Q2 25
$2.2B
$262.4M
Q1 25
$2.3B
$321.4M
Q4 24
$2.3B
$387.2M
Q3 24
$2.4B
$451.8M
Q2 24
$2.0B
$489.0M
Q1 24
$2.0B
$403.4M
Debt / Equity
BPRN
BPRN
STRO
STRO
Q4 25
Q3 25
0.00×
Q2 25
0.04×
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BPRN
BPRN
STRO
STRO
Operating Cash FlowLast quarter
$21.5M
$-177.2M
Free Cash FlowOCF − Capex
$20.6M
FCF MarginFCF / Revenue
99.3%
Capex IntensityCapex / Revenue
4.3%
Cash ConversionOCF / Net Profit
3.54×
TTM Free Cash FlowTrailing 4 quarters
$29.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BPRN
BPRN
STRO
STRO
Q4 25
$21.5M
$-177.2M
Q3 25
$4.9M
$-38.2M
Q2 25
$3.1M
$-44.7M
Q1 25
$1.3M
$-67.9M
Q4 24
$14.7M
$-71.7M
Q3 24
$1.2M
$-64.5M
Q2 24
$4.3M
$9.5M
Q1 24
$4.8M
$-64.7M
Free Cash Flow
BPRN
BPRN
STRO
STRO
Q4 25
$20.6M
Q3 25
$4.7M
Q2 25
$2.9M
Q1 25
$1.1M
Q4 24
$13.2M
Q3 24
$766.0K
Q2 24
$3.9M
Q1 24
$4.8M
FCF Margin
BPRN
BPRN
STRO
STRO
Q4 25
99.3%
Q3 25
21.6%
Q2 25
13.7%
Q1 25
5.0%
Q4 24
65.9%
Q3 24
4.0%
Q2 24
21.8%
Q1 24
27.3%
Capex Intensity
BPRN
BPRN
STRO
STRO
Q4 25
4.3%
Q3 25
1.1%
Q2 25
1.2%
Q1 25
1.0%
Q4 24
7.6%
Q3 24
2.2%
Q2 24
2.1%
Q1 24
0.4%
Cash Conversion
BPRN
BPRN
STRO
STRO
Q4 25
3.54×
Q3 25
0.76×
Q2 25
4.57×
Q1 25
0.23×
Q4 24
2.82×
Q3 24
Q2 24
0.84×
Q1 24
1.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons